ViroGates A/S (VIRO) - Total Assets
Based on the latest financial reports, ViroGates A/S (VIRO) holds total assets worth Dkr26.77 Million DKK (≈ $4.19 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
ViroGates A/S - Total Assets Trend (2015–2025)
This chart illustrates how ViroGates A/S's total assets have evolved over time, based on quarterly financial data. Also see VIRO company net worth for the company's overall valuation and market capitalisation.
ViroGates A/S - Asset Composition Analysis
Current Asset Composition (December 2025)
ViroGates A/S's total assets of Dkr26.77 Million consist of 99.4% current assets and 0.6% non-current assets. Review ViroGates A/S balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (DKK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Dkr0.00 | 86.0% |
| Accounts Receivable | Dkr1.52 Million | 5.0% |
| Inventory | Dkr1.75 Million | 5.7% |
| Property, Plant & Equipment | Dkr0.00 | 0.0% |
| Intangible Assets | Dkr0.00 | 0.0% |
| Goodwill | Dkr0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how ViroGates A/S's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See VIRO live share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ViroGates A/S's current assets represent 99.4% of total assets in 2025, an increase from 97.5% in 2015.
- Cash Position: Cash and equivalents constituted 86.0% of total assets in 2025, up from 83.3% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is inventory at 5.7% of total assets.
ViroGates A/S Competitors by Total Assets
Key competitors of ViroGates A/S based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
COCHLEAR LTD ADR 1/2/O.N.
F:OC50
|
Germany | €2.83 Billion |
|
TransMedics Group Inc
NASDAQ:TMDX
|
USA | $1.46 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.89 Billion |
|
Novocure Ltd
NASDAQ:NVCR
|
USA | $787.93 Million |
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.20 Billion |
|
Hangzhou AGS MedTech Co. Ltd. A
SHG:688581
|
China | CN¥2.70 Billion |
|
Nanjing Vishee Medical Technology Co Ltd
SHG:688580
|
China | CN¥1.79 Billion |
ViroGates A/S - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.82 | 4.24 | 8.61 |
| Quick Ratio | 3.59 | 3.66 | 7.95 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Dkr19.62 Million | Dkr12.10 Million | Dkr24.27 Million |
ViroGates A/S - Advanced Valuation Insights
This section examines the relationship between ViroGates A/S's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.03 |
| Latest Market Cap to Assets Ratio | 0.48 |
| Asset Growth Rate (YoY) | 73.2% |
| Total Assets | Dkr30.59 Million |
| Market Capitalization | $14.67 Million USD |
Valuation Analysis
Below Book Valuation: The market values ViroGates A/S's assets below their book value (0.48x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: ViroGates A/S's assets grew by 73.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for ViroGates A/S (2015–2025)
The table below shows the annual total assets of ViroGates A/S from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Dkr30.59 Million ≈ $4.79 Million |
+73.21% |
| 2024-12-31 | Dkr17.66 Million ≈ $2.76 Million |
-28.08% |
| 2023-12-31 | Dkr24.55 Million ≈ $3.84 Million |
+40.00% |
| 2022-12-31 | Dkr17.54 Million ≈ $2.74 Million |
-13.30% |
| 2021-12-31 | Dkr20.23 Million ≈ $3.16 Million |
-47.11% |
| 2020-12-31 | Dkr38.25 Million ≈ $5.98 Million |
-15.30% |
| 2019-12-31 | Dkr45.16 Million ≈ $7.07 Million |
-28.80% |
| 2018-12-31 | Dkr63.42 Million ≈ $9.92 Million |
+1174.07% |
| 2017-12-31 | Dkr4.98 Million ≈ $778.84K |
-58.51% |
| 2016-12-31 | Dkr12.00 Million ≈ $1.88 Million |
-31.11% |
| 2015-12-31 | Dkr17.41 Million ≈ $2.72 Million |
-- |
About ViroGates A/S
ViroGates A/S, an in vitro diagnostics company, develops and sells blood tests for measuring chronic inflammation for the healthcare sector. It offers suPARnostic TurbiLatex, a CE-IVD approved particle-enhanced turbidimetric immunoassay for quantitative measurement of suPAR in human plasma; suPARnostic AUTO Flex ELISA kit, a fully quantitative immunoassay designed for accurate and reliable measur… Read more